Showing results (1-10 of 482) with videos related to
Sort By:
Pageof 49
Trends in Molecular Medicine|November 8, 2003
Immunofocusing: antigen engineering to promote the induction of HIV-neutralizing antibodiesRalph Pantophlet, Dennis R BurtonAnnual Review of Immunology|March 23, 2006
GP120: target for neutralizing HIV-1 antibodiesRalph Pantophlet, Dennis R BurtonJournal of Virology|April 30, 2003
Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine designRalph Pantophlet, Ian A Wilson, Dennis R BurtonVaccine|December 7, 2011
An engineered mutant of HIV-1 gp120 formulated with adjuvant Quil A promotes elicitation of antibody responses overlapping the CD4-binding siteFatima K Ahmed, Brenda E Clark, Dennis R Burton, et al.Journal of Virology|November 28, 2008
The human immunodeficiency virus type 1 envelope spike of primary viruses can suppress antibody access to variable regionsRalph Pantophlet, Meng Wang, Rowena O Aguilar-Sino, et al.Virology|September 30, 2008
Neutralizing activity of antibodies to the V3 loop region of HIV-1 gp120 relative to their epitope fine specificityRalph Pantophlet, Terri Wrin, Lisa A Cavacini, et al.Journal of Virology|September 15, 2005
Comparing antigenicity and immunogenicity of engineered gp120Suganya Selvarajah, Bridget Puffer, Ralph Pantophlet, et al.Virology|April 10, 2007
Analysis of the neutralization breadth of the anti-V3 antibody F425-B4e8 and re-assessment of its epitope fine specificity by scanning mutagenesisRalph Pantophlet, Rowena O Aguilar-Sino, Terri Wrin, et al.Current Pharmaceutical Design|December 7, 2010
Antibody epitope exposure and neutralization of HIV-1Ralph PantophletJournal of Virology|December 13, 2002
Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120Ralph Pantophlet, Erica Ollmann Saphire, Pascal Poignard, et al.Pageof 49